A pilot study assessing safety and antiretroviral activity of intravenously administered LTB4 [leukotriene B4] in HIV-1 infected adults with a CD4 count greater than 250 cells/mm3 and a viral load greater than 5,000 copies/mL, and who have not received antiretroviral therapy within two months

Trial Profile

A pilot study assessing safety and antiretroviral activity of intravenously administered LTB4 [leukotriene B4] in HIV-1 infected adults with a CD4 count greater than 250 cells/mm3 and a viral load greater than 5,000 copies/mL, and who have not received antiretroviral therapy within two months

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2006

At a glance

  • Drugs Leukotriene B4 (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors LTB4 AB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Nov 2006 Status change
    • 26 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top